Dr. Carrillo has a wide range of responsibilities, including oversight of the Association's granting process and communication of scientific findings within and outside of the organization. Dr. Carrillo is responsible for overseeing the international science division for the Alzheimer’s Association and is responsible for sharing the global landscape of research and ongoing investigations with a wide range of constituents.
Carl V. Hill, Ph.D., MPH, is the chief diversity, equity and inclusion officer for the Alzheimer’s Association, overseeing strategic initiatives to strengthen the Association’s outreach to all populations, and providing communities with resources and support to address the Alzheimer’s crisis.
There is a well-recognized need for diversity in clinical trial populations to ensure diagnostics and treatments are safe and effective for everyone. It’s imperative that the [AD] community is aware of the impact of historical racism and also the current racial discrimination in health care that presents obstacles for inclusive participation in [AD] trials. ... Just as important, it is critical that we evaluate strategies that have been shown to be effective when recruiting historically underrepresented individuals and communities in these vital [AD] research studies.25 October 2021
This FDA drug approval ushers in a new era in Alzheimer's treatment and research. History has shown us that approvals of the first drug in a new category invigorates the field, increases investments in new treatments and encourages greater innovation. We are hopeful and this is the beginning — both for this drug and for better treatments for Alzheimer's.25 October 2021